No benefit from famotidine on COVID-19 outcomes

There was no reduced risk for COVID-19 outcomes among hospitalized patients treated with famotidine, according to study results.“Several observational studies have investigated the effect of famotidine on COVID-19 outcomes but have been limited to single-institutional explorations of small samples with varying statistical methods and inconsistent results,” Azza Shoaibi, PhD, from Janssen Research and Development, and colleagues wrote. “Real-world data can potentially provide critical and timely evidence on the effectiveness of famotidine on improving COVID-19 outcomes.”Read More

Share on facebook
Share on twitter
Share on linkedin